Introducing Invitee Digital Health – A personalized health management platform that leverages genomic information to inform health decisions for patients and clinicians


– Invitae Launches Seamless Digital Platform to Improve Patient and Provider Experiences and Bring Genetics Further to Traditional Medicine –

SAN FRANCISCO, March 29, 2022 /PRNewswire/ — Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of Invitae Digital Health, a connected digital health platform that informs health decisions through to actionable genomic information for patients and clinicians.

With Invitae Digital Health, healthcare providers and health systems use a single, transparent platform that integrates important health data across the lifespan of each patient. Grounded in genetic knowledge and evolutionary at the population level, it will enable a holistic approach to the personalized health management of individuals throughout their health journey.

Ushering in a new era of proactive healthcare
With 19.3 million new cases of cancer worldwide in 2020, 420 million cases of cardiovascular disease28 million children are born each year with a serious genetic disease in the world3and 99% of people with a genetic variation that may impact drug response4the potential impact of genetics on traditional health care is profound.

A modular platform tailored to the needs of health systems and their patients, Invitae Digital Health will encourage healthcare providers to move away from the traditional model of reactive healthcare and towards a new era of proactive and based care. on the population. By enabling the identification of disease risk earlier in the continuum of care, the platform is poised to help providers and patients improve early detection and better personalize treatments with the goal of achieving better outcomes. results and reduce the burden on the broader health system.

“Invitae has completed more than six software acquisitions since 2019 with a vision for a unified platform that can uncover actionable genomic information to help keep large populations healthy or better manage disease,” said Kamal Gogineni, President, Digital Health at Invitee. “The next step is Invitae Digital Health, a personalized health management platform at the intersection of genetics and real-world clinical data. Its launch cements Invitee’s commitment to advancing medicine for the benefit of patients and clinicians.

While existing population health solutions are positioned solely for point-of-care oncology testing, Invitae Digital Health brings genomics to mainstream medicine in a wide range of places where care is impacted – cardiology, management pharmacogenomics, rare diseases, neurology, pediatrics, women’s health and oncology (pre- and post-diagnosis).

“Invitae Digital Health is designed to synthesize and humanize clinical and genetic information to enable individuals and their care teams to make informed healthcare decisions,” said Rakesh Patel, MD, Chief Medical Officer, Digital Health at Invitae. “We are proud to offer a much-needed solution that we hope will propel the use of genetic knowledge in traditional medicine.”

Modular suite of tools for health systems to customize workflows
Invitae Digital Health will provide healthcare systems with a fully integrated suite of customizable tools in a single, intuitive platform. Capabilities include:

  • Seamless integrations with electronic health record solutions
  • Clinical decision support to help clinicians determine which patients should undergo genetic testing or additional imaging
  • Use of medical management guidelines, which are continuously updated to stay current
  • Scalable and secure data exchange using industry standard protocols

“Invitae Digital Health will be a powerful channel for health systems to deliver proactive healthcare, which is crucial as disease rates rise and hospitals remain overstretched,” said Burns C. Blaxall, Ph. D., executive director of Precision Medicine at The Christ. Hospital health network. “As genomics takes hold in mainstream medicine, providers need to easily know who to test, what test to order, and how to act on that information based on the latest evidence both today and in the future. future – and Invitae Digital Health is making this possible across multiple clinical areas.”

Healthcare providers can learn more about Invitae Digital Health here.


1 ACS publication of the International Agency for Research on Cancer: Sung, H, Ferlay, J, Siegel, RL, Laversanne, M, Soerjomataram, I, Jemal, A, BrayF. World cancer statistics
2 Roth GA, Johnson C, Abajobir A, et al. Global, regional and national burden of cardiovascular disease for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1-25.
3 March of Dimes. World Report on Birth Defects. 2006.
4 McInnes G, et al. Clin Pharmacol Ther. 2021;109(6):1528–1537
5 Haverfield EV et al. Physician-directed genetic screening to assess personal risk for medically actionable disorders: a large, multicenter cohort study. BMC Med. 2021 Aug 18;19(1):199. doi:10.1186/s12916-021-01999-2

About Invite
Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information to traditional medicine to improve health care for billions of people. Invitee’s goal is to consolidate genetic testing from around the world into one service with better quality, faster turnaround times and lower prices. For more information, visit the company’s website at

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the availability, functionality and potential impact of Invitee Digital Health; the company’s beliefs regarding the potential impact of genetics on traditional medicine; the company’s beliefs that Invitae Digital Health will encourage healthcare providers to evolve into a new era of proactive, population-based care; and the company’s belief that Invitae Digital Health can help improve early detection and better personalize treatments with the goal of achieving better outcomes and reducing the burden on the broader healthcare system. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those reported and should not be relied upon as an indication of future performance. These risks and uncertainties include, but are not limited to: the company’s loss history; the company’s ability to be competitive; the company’s inability to effectively manage growth; the company’s need to evolve its infrastructure in anticipation of demand for its testing and to increase demand for its testing; the company’s ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, data loss and other disruptions; the laws and regulations applicable to the company’s activity; and other risks disclosed in the company’s filings with the Securities and Exchange Commission, including the risks disclosed in the company’s annual report on Form 10-K for the fiscal year ended December 31, 2021. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

Amy Hadsock
[email protected]
(628) 213-3283

SOURCE Invite Corporation


Comments are closed.